Politics, Policy & Law
U.K.’s opportunity as changes come to MHRA, NICE
New MHRA pathways and a greater risk tolerance at NICE could make the U.K. an attractive destination for drug developers
New MHRA pathways and a greater risk tolerance at NICE could make the U.K. an attractive destination for drug developers.
On the cusp of a new era outside of Europe, the U.K. has an opportunity to create an innovative and interconnected regulatory and reimbursement system that can attract biopharma by accelerating patient access to new medicines. Doing so will require aligning the risk appetites of the regulator MHRA, the HTA body NICE, and NHS England — anything short of this would likely result in a continuation of the same access challenges that have hindered access to new medicines over the past two decades.
With about six weeks to go before the U.K. officially leaves the EU, there are real opportunities and ambition for a step change in how the U.K. approves and pays for new drugs.
U.K. regulator Medicines and Healthcare products Regulatory Agency (MHRA) has published guidance on a set